People: Sorrento Therapeutics Inc (SRNE.PK)

SRNE.PK on OTC Markets Group

0.20USD
14 May 2013
Price Change (% chg)

$0.01 (+5.26%)
Prev Close
$0.19
Open
$0.20
Day's High
$0.20
Day's Low
$0.20
Volume
30,000
Avg. Vol
35,726
52-wk High
$0.51
52-wk Low
$0.06

Search Stocks

Summary

Name Age Since Current Position

Glenn Halpryn

 51 2011 Independent Chairman of the Board

Henry Ji

 48 2012 President, Chief Executive Officer, Director

Richard Vincent

 49 2010 Chief Financial Officer

Jane Hsiao

 65 2010 Independent Director

Kim Janda

 54 2011 Independent Director

Curtis Lockshin

 52 2008 Independent Director

M. Scott Salka

 50 2012 Independent Director

Diane Tang-Liu

 55 2012 Independent Director
» Insider Trading

Biographies

Name Description

Glenn Halpryn

 Mr. Glenn L. Halpryn is an Independent Chairman of the Board of Sorrento Therapeutics Inc. He has served as a director since July 2008 and as Chairman of the Board since April 2011. From July 2008 to August 2009, Mr. Halpryn served as Chairman of the Board, Chief Executive Officer and President. Since August 2010, Mr. Halpryn has served as a Director of ChromaDex Corporation, a publicly traded company that supplies phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. From April 2010 until October 2011, Mr. Halpryn served as a Director of CDSI Holdings, Inc., a public shell company seeking new business opportunities. Since 2001, Mr. Halpryn has served as Chief Executive Officer and a director of Transworld Investment Corporation and is an active investor and management member of investor groups in various land acquisition and development projects. Since September 2008, Mr. Halpryn has served as a director of Castle Brands Inc., a developer and international marketer of premium branded spirits whose shares are traded on the NYSE Amex (formerly known as the American Stock Exchange). From December 2008 until June 2011, Mr. Halpryn served as a director of SearchMedia Holdings Limited, an outdoor billboard and in-elevator advertisement company in China. From September 2008 until August 2010, Mr. Halpryn served as a director of Winston Pharmaceuticals, Inc., a publicly held corporation specializing in the manufacture of skin creams and prescription medication for the treatment of pain management.

Henry Ji

 Dr. Henry Ji, Ph.D., is President, Chief Executive Officer, Director of Sorrento Therapeutics Inc. He co-founded Sorrento Therapeutics, Inc. in January 2006 and served as its Chief Scientific Officer since November 2008, as a director since January 2006, and as its Interim Chief Executive Officer since April 2011. Dr. Ji also served as Secretary from September 2009 to June 2011. Dr. Ji was appointed to serve as Chief Scientific Officer effective upon acquisition of Sorrento Therapeutics, Inc. in September 2009. In 2002, Dr. Ji founded BioVintage, Inc., a research and development company focusing on innovative life science technology and product development, and has served as its President since 2002. From 2001 to 2002, Dr. Ji served as Vice President of CombiMatrix Corporation, a publicly traded biotechnology company that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix, Dr. Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as Vice President, of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and development. In 1997, Dr. Ji co-founded Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999. Dr. Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento Therapeutics Inc.’s intellectual property. Dr. Ji has a Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University.

Richard Vincent

 Mr. Richard G. Vincent is Chief Financial Officer of Sorrento Therapeutics Inc. He joined the Company in January 2010, and has served as Chief Financial Officer, on a part-time basis, since February 2010. Since April 2008, Mr. Vincent has served as a contract Chief Financial Officer for various other companies, including Elevation Pharmaceuticals, Inc., Genoa Pharmaceuticals, Inc., Meritage Pharma, Inc., Verus Pharmaceuticals, Inc., Chumby Industries, Inc. and Suneva Medical, Inc. From October 2004 to March 2009, Mr. Vincent served as Chief Financial Officer of Verus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing pediatric drug/device combination products for the treatment of asthma, allergies, and related diseases and conditions. From October 2003 to October 2004, Mr. Vincent served as Chief Financial Officer of Women First HealthCare, Inc., a public specialty pharmaceutical company focused on women’s healthcare and dermatology. Mr. Vincent also served as Senior Director of Finance for Elan Pharmaceuticals, Inc., a public biopharmaceutical company engaged in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain, from October 2001 to October 2003. From November 1995 to October 2001, Mr. Vincent served in senior management capacities for several wireless and technology companies. From 1987 to 1995, Mr. Vincent held a number of positions with Deloitte & Touche LLP, the last of which was senior manager, where he specialized in emerging growth and publicly-reporting companies. Mr. Vincent became a Certified Public Accountant in California in 1989 and holds a B.S. degree in business with an emphasis in accounting from San Diego State University.

Jane Hsiao

 Dr. Jane H. Hsiao is an Independent Director of Sorrento Therapeutics Inc., since January 25, 2010. Dr. Hsiao has served as Vice-Chairman and Chief Technical Officer of OPKO, a publicly traded specialty healthcare company, since May 2007. Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX from 1995 to January 2006. Dr. Hsiao served as Chairman, Chief Executive Officer and President of IVAX Animal Health, IVAX’s veterinary products subsidiary, from 1998 to 2006. Dr. Hsiao has served as Chairman of the Board of each of Safestitch Medical, Inc. and Non-Invasive Monitoring Systems, Inc., or NIMS, both medical device companies, since September 2007 and October 2008, respectively. Dr. Hsiao has served as Interim CEO of NIMS since February 2012. Dr. Hsiao is also a director of PROLOR Biotech, Inc., a development stage biopharmaceutical company, and Neovasc, Inc., a company developing and marketing medical specialty vascular devices. Previously Dr. Hsiao served on the boards of directors of IVAX Diagnostics and Protalix BioTherapeutics, Inc.

Kim Janda

 Dr. Kim D. Janda is an Independent Director of Sorrento Therapeutics, Inc., since April 2012. Dr. Janda has served as Ely R. Callaway, Jr. Chaired Professor in the Departments of Chemistry, Immunology and Microbial Science at The Scripps Research Institute since 1996 and as the Director of the Worm Institute of Research and Medicine (WIRM) at The Scripps Research Institute since 2005. Furthermore, Dr. Janda has served as a Skaggs Scholar within the Skaggs Institute of Chemical Biology, also at The Scripps Research Institute, since 1996. Dr. Janda holds a B.S. degree from the University of South Florida in Clinical Chemistry and a doctoral degree from the University of Arizona with Robert B. Bates in natural product total synthesis. A hallmark of his research is that Dr. Janda has been able to uniquely combine principles of medicinal chemistry together with modern molecular biology, immunology and neuropharmacology, allowing the creation of both synthetic/natural molecules and processes with biological, chemical and physical properties. Dr. Janda serves on the Scientific Advisory Boards of Materia, Inc. and Singapore Ministry of Education (MOE), EP1 Physical Sciences.

Curtis Lockshin

 Dr. Curtis A. Lockshin is an Independent Director of Sorrento Therapeutics Inc., since July 2008. Since October 3, 2011, Dr. Lockshin has served as Vice President, Corporate R&D Initiatives at OPKO. From 2003 until September 30, 2011, Dr. Lockshin served as an independent pharmaceutical and life sciences consultant, focused on small companies that seek to leverage their technology assets inside healthcare, biotechnology and security sectors. Dr. Lockshin served as a director of Winston Pharmaceuticals, Inc., a publicly held corporation and the parent company of Winston Laboratories, Inc., from September 2008 until May 2010. Dr. Lockshin served as a director of Getting Ready Corporation, a publicly held shell corporation, from December 2006 until its merger with Winston Laboratories in September 2008. Dr. Lockshin served as a director of clickNsettle.com, Inc., a publicly held shell corporation, from October 2007 until its merger with Cardo Medical, LLC in September 2008. Dr. Lockshin was a director of Orthodontix, Inc. from July 2006 until December 2006. From 1998 to 2002, Dr. Lockshin was a Scientist, Associate Director, and Director of Discovery Biology & Informatics at Sepracor Inc., where he was instrumental in establishing the New Leads program, which delivered novel chemical entities into the company’s preclinical pipeline. In 2002-2003, while Director of Discovery Biology at Beyond Genomics, Inc., Dr. Lockshin co-developed strategies for utilizing proprietary technology platforms in clinical trial optimization and prediction of off-target drug activities. He holds a Bachelor’s degree in Life Sciences and a PhD in Biological Chemistry, both from the Massachusetts Institute of Technology.

M. Scott Salka

 Mr. M. Scott Salka is an Independent Director of Sorrento Therapeutics, Inc., since February 23, 2012. Mr. Salka currently serves as CEO of Aspyrian, CendR, and Vesper Biologics, all biotechnology companies. Previously, from 2001-2010, Mr. Salka served as CEO of Ambit Biosciences, a biotechnology company in San Diego, California. Since 2009, Mr. Salka has served on the Board of Directors of San Diego State University School of Business and has served on the Board of Directors of BIOCOM, the regional life science association in the world, since 2007. Mr. Salka holds an MBA from Carnegie Mellon University and a B.S. in Finance from San Diego State University.

Diane Tang-Liu

 Dr. Diane D. S. Tang-Liu is an Independent Director of Sorrento Therapeutics, Inc., since February 23, 2012. Dr. Tang-Liu currently serves as the Vice President, Clinical Pharmacology, Global Drug Development at Allergen, Inc. in Irvine, California, and has been employed by Allergen in positions of responsibility since 1981. Dr. Tang-Liu serves as an adjunct Professor at USC – School of Pharmacy & Department of Pharmacology and Pharmaceutical Sciences in Los Angeles, California. Dr. Tang-Liu holds a Ph.D. in Pharmaceutical Chemistry from University of California, San Francisco and a B.S. in Pharmacy from National Taiwan University, Taipei, Taiwan, R.O.C. Dr. Tang-Liu is a fellow of the American Association of Pharmaceutical Scientis and the American College of Clinical Pharmacology.

Basic Compensation

Name Fiscal Year Total

Glenn Halpryn

 14,543

Henry Ji

 262,371

Richard Vincent

 181,025

Jane Hsiao

 --

Kim Janda

 --

Curtis Lockshin

 --

M. Scott Salka

 --

Diane Tang-Liu

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

Glenn Halpryn

 0 0

Henry Ji

 0 0

Richard Vincent

 0 0

Jane Hsiao

 0 0

Kim Janda

 0 0

Curtis Lockshin

 0 0

M. Scott Salka

 0 0

Diane Tang-Liu

 0 0

Insider Trading

Name Shares Traded Price

JI HENRY

 6,250,000 $0.16

JI HENRY

 150,000 $0.00

JI HENRY

 150,000 $0.00

JI HENRY

 150,000 $0.00

JI HENRY

 150,000 $0.00

SCIFRES DONALD R

 12,500,000 $0.16

SCIFRES DONALD R

 9,813,880 $0.00
» Full list on Insider Trading
Search Stocks